Cancer-specific glycosylation of CD13 impacts its detection and activity in preclinical cancer tissues

Harnessing the differences between cancer and non-cancer tissues presents new opportunities for selective targeting by anti-cancer drugs. CD13, a heavily glycosylated protein, is one example with significant unmet clinical potential in cancer drug discovery. Despite its high expression and activity...

Descripción completa

Detalles Bibliográficos
Autores principales: Barnieh, Francis M., Galuska, Sebastian P., Loadman, Paul M., Ward, Simon, Falconer, Robert A., El-Khamisy, Sherif F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628746/
https://www.ncbi.nlm.nih.gov/pubmed/37942010
http://dx.doi.org/10.1016/j.isci.2023.108219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628746/
https://www.ncbi.nlm.nih.gov/pubmed/37942010
http://dx.doi.org/10.1016/j.isci.2023.108219

Ejemplares similares